Literature DB >> 34076845

Peripheral Versus Intraparenchymal Papillary Thyroid Microcarcinoma: Different Morphologies and PD-L1 Expression.

Bozidar Kovacevic1, Dragana Vucevic2, Snezana Cerovic3, Catarina Eloy4,5,6.   

Abstract

Peripheral localisation of papillary thyroid microcarcinoma (PTMC), in comparison with intraparenchymal PTMC (i-PTMC) is related to some clinicopathological features related with biological aggressiveness, including lymph node metastasis (LNM). The expression of PD-L1 in tumour cell has been associated with increased tumour survival, progression, and potentially an aggressive clinical course. This study evaluates the relation between clinicopathological features of PTMC, including tumour localisation, with PD-L1 immunoexpression. The study included 99 patients with the histological diagnosis of PTMC (≥ 5 mm). PD-L1 protein expression was assessed by immunohistochemistry. PTMCs were divided into the four following groups: G1- peripherally localised PTMC (p-PTMC) with PD-L1 expression; G2-p-PTMC without PD-L1 expression; G3-i-PTMC with PD-L1 expression and G4-i-PTMC without PD-L1 expression. G1 was the most frequent (n = 46; 46.5%), followed by G4 (n = 25; 25.3%) and similar distribution of G3 (n = 15; 15.2%) and G2 (n = 13; 13.1%). In comparison with other groups, G1 was significantly associated with classical morphology, invasive growth, lymphatic invasion (LI), vascular invasion (VI), psammoma bodies, intratumoral fibrosis, PD-L1 positive tumour-infiltrating lymphocytes, and multinuclear giant cells (MGCs). G4 more commonly exhibited follicular morphology, expansive/circumscribed growth, and absence of the following: intratumoural fibrosis, LI, VI, psammoma bodies, PD-L1 positive tumour-infiltrating lymphocytes, and MGCs. LNMs were significantly more frequent in G1 in comparison with the other groups (p = 0.000). In conclusion, morphology and tumour microenvironment of p-PTMC with PD-L1 expression is different from i-PTMC without PD-L1 expression. The differences between these two groups of PTMC include clinicopathological features related with biological aggressiveness such as the occurrence of LNM.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Lymphatic metastasis; PD-L1; Thyroid papillary microcarcinoma; Tumour microenvironment

Mesh:

Substances:

Year:  2021        PMID: 34076845      PMCID: PMC9018942          DOI: 10.1007/s12105-021-01337-1

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  46 in total

1.  THYROID CARCINOMA. CLASSIFICATION, INTRAGLANDULAR DISSEMINATION, AND CLINICOPATHOLOGICAL STUDY BASED UPON WHOLE ORGAN SECTIONS OF 80 GLANDS.

Authors:  W O RUSSELL; M L IBANEZ; R L CLARK; E C WHITE
Journal:  Cancer       Date:  1963-11       Impact factor: 6.860

2.  Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.

Authors:  Rong-Liang Shi; Ning Qu; Ting-Xian Luo; Jun Xiang; Tian Liao; Guo-Hua Sun; Yu Wang; Yu-Long Wang; Cai-Ping Huang; Qing-Hai Ji
Journal:  Thyroid       Date:  2017-01-24       Impact factor: 6.568

Review 3.  Regulation and Function of the PD-L1 Checkpoint.

Authors:  Chong Sun; Riccardo Mezzadra; Ton N Schumacher
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

4.  Lymphovascular invasion of papillary thyroid carcinoma revisited in the era of active surveillance.

Authors:  Shih-Ping Cheng; Jie-Jen Lee; Ming-Nan Chien; Chi-Yu Kuo; Jie-Yang Jhuang; Chien-Liang Liu
Journal:  Eur J Surg Oncol       Date:  2020-07-20       Impact factor: 4.424

5.  Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients.

Authors:  R Katoh; J Sasaki; H Kurihara; K Suzuki; Y Iida; A Kawaoi
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

6.  Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.

Authors:  Jill J Bastman; Hilary S Serracino; Yuwen Zhu; Michelle R Koenig; Valerica Mateescu; Sharon B Sams; Kurtis D Davies; Christopher D Raeburn; Robert C McIntyre; Bryan R Haugen; Jena D French
Journal:  J Clin Endocrinol Metab       Date:  2016-04-05       Impact factor: 5.958

7.  Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma.

Authors:  Yanhua Bai; Gengyin Zhou; Misa Nakamura; Takashi Ozaki; Ichiro Mori; Emiko Taniguchi; Akira Miyauchi; Yasuhiro Ito; Kennichi Kakudo
Journal:  Mod Pathol       Date:  2009-03-20       Impact factor: 7.842

8.  The Expression of Tumor-Associated Macrophages and Multinucleated Giant Cells in Papillary Thyroid Carcinoma.

Authors:  Maya Vladova Gulubova; Koni Vancho Ivanova
Journal:  Open Access Maced J Med Sci       Date:  2019-12-10

Review 9.  Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting.

Authors:  Ronald Ghossein; Justine A Barletta; Martin Bullock; Sarah J Johnson; Kennichi Kakudo; Alfred K Lam; Mufaddal T Moonim; David N Poller; Giovanni Tallini; R Michael Tuttle; Bin Xu; Anthony J Gill
Journal:  Hum Pathol       Date:  2020-09-10       Impact factor: 3.466

10.  Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma.

Authors:  Bo-Yeon Kim; Chan-Hee Jung; Jae-Wook Kim; Seung-Won Lee; Chul-Hee Kim; Sung-Koo Kang; Ji-Oh Mok
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

View more
  2 in total

1.  Lymphatic Vessel Invasion in Routine Pathology Reports of Papillary Thyroid Cancer.

Authors:  Costanza Chiapponi; Hakan Alakus; Matthias Schmidt; Michael Faust; Christiane J Bruns; Reinhard Büttner; Marie-Lisa Eich; Anne M Schultheis
Journal:  Front Med (Lausanne)       Date:  2022-02-21

2.  EWSR1 rearrangement in papillary thyroid microcarcinoma is related to classic morphology and the presence of small-cell phenotype.

Authors:  Bozidar Kovacevic; Ana Caramelo; Vesna Skuletic; Snezana Cerovic; Catarina Eloy
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.